Bausch + Lomb Announces Launch of $1.4B Proposed Financing for Acquisition of XIIDRA
Portfolio Pulse from Benzinga Newsdesk
Bausch + Lomb Corporation (TSX:BLCO) has announced the launch of a $1.4 billion financing initiative for the acquisition of XIIDRA, a non-steroid eye drop product. The financing includes an offering of new senior secured notes due 2028 and a proposed incremental term loan facility. The proceeds will be used to fund the acquisition, pay related fees and expenses, and for general corporate purposes, including debt repayment.
September 11, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bausch + Lomb's acquisition of XIIDRA, funded by a $1.4 billion financing initiative, could potentially strengthen the company's position in the eye health market.
The acquisition of XIIDRA, a product specifically approved to treat dry eye disease, could potentially expand Bausch + Lomb's product portfolio and strengthen its position in the eye health market. The successful financing of this acquisition could also demonstrate the company's financial capability and strategic planning.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100